Key terms
About OTLK
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest OTLK news
Apr 17
8:31am ET
Four new option listings on April 17th
Mar 28
5:04pm ET
Outlook Therapeutics files $300M mixed securities shelf
Mar 27
9:47am ET
Spotify initiated, Lowe’s downgraded: Wall Street’s top analyst calls
Mar 27
6:35am ET
Outlook Therapeutics upgraded to Buy from Neutral at BTIG
Mar 26
4:33pm ET
Outlook Therapeutics Grants Stock Options to Top Executives
Mar 25
4:13pm ET
Outlook Therapeutics files to sell 21.43M shares of common stock for holders
Mar 25
8:35am ET
Outlook Therapeutics: Buy Rating Affirmed Amid Positive European Developments and Anticipated U.S. Market Success
Mar 24
10:45pm ET
Buy Rating Affirmed for Outlook Therapeutics: European Endorsement and Pivotal US Study Progress Signal Strong Market Potential
Mar 22
9:35am ET
Outlook Therapeutics Inc trading resumes
Mar 22
9:30am ET
Outlook Therapeutics Inc trading halted, volatility trading pause
Mar 22
7:38am ET
Outlook Therapeutics announces CHMP of EMA issued positive opinion on ONS-5010
Mar 18
11:45pm ET
Buy Rating Affirmed for Outlook Therapeutics Amidst Strong Financial Positioning and Advancing Clinical Trials
Mar 18
11:03am ET
Biotech Alert: Searches spiking for these stocks today
Mar 15
10:11am ET
Outlook Therapeutics Inc trading resumes
Mar 15
10:06am ET
Outlook Therapeutics Inc trading halted, volatility trading pause
Mar 13
7:50pm ET
Outlook Therapeutics Inc trading halted, news pending
Mar 12
8:23am ET
Outlook Therapeutics announces effective date for 1-for-20 reverse stock split
Feb 16
8:15am ET
Buy Rating Affirmed for Outlook Therapeutics Amidst Promising Market Prospects for ONS-5010/Lytenava
Feb 15
7:14am ET
Outlook Therapeutics upgraded to Buy from Neutral at Chardan
Feb 15
6:27am ET
Buy Rating Affirmed for Outlook Therapeutics on Strategic Progress and Strong Financial Positioning
Feb 15
6:14am ET
Outlook Therapeutics price target lowered to $1.50 from $2 at H.C. Wainwright
Feb 14
8:08am ET
Outlook Therapeutics reports Q1 EPS (4c), consensus (5c)
Jan 31
8:12am ET
Outlook Therapeutics doses first subject in NORSE EIGHT trial
Jan 26
11:25am ET
Biotech Alert: Searches spiking for these stocks today
Jan 25
11:38am ET
Biotech Alert: Searches spiking for these stocks today
Jan 25
11:38am ET
Biotech Alert: Searches spiking for these stocks today
Jan 25
6:21am ET
Outlook Therapeutics upgraded to Buy from Neutral at Guggenheim
Jan 25
5:35am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jan 25
5:18am ET
Outlook Therapeutics upgraded to Buy from Hold at Brookline
Jan 25
4:01am ET
Outlook Therapeutics Announces Private Placement and Note Amendment
Jan 25
4:01am ET
Outlook Therapeutics Executes Unregistered Equity Sales
No recent press releases are available for OTLK
OTLK Financials
Key terms
Ad Feedback
OTLK Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
OTLK Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range